인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
FOXM1 (forkhead box protein M1) is a member of the transcription factors (TF) in the forkhead (FOX) family. Numerous studies over the past several years have progressively contributed to our current understanding of FOXM1 functions. Early work characterized FOXM1 as a proliferation-associated mammalian TF that controls cell cycle-transcriptional program, and is essential for proper mitotic function and genomic stability in normal cells. However, FOXM1 is aberrantly high-expressed in the majority of human cancers. A large body of literature from different studies has demonstrated FOXM1 as a critical molecule that regulates multiple aspects of cancer cells and maintains all major cancer hallmarks. In addition, recent studies have documented FOXM1 in cancer therapy resistance. Indeed, FOXM1 is repeatedly identified as a common factor associated with the higher cancer stage and weaker response to cancer therapies by regulating several targets relevant to drug response and cell survival. FOXM1-dependent transcriptional activity and downstream pathways regulate multiple functions in response to drug-induced genotoxic stress, oxidative stress, and mitotic catastrophe. FOXM1 also interacts with other proteins, and these protein-protein interactions regulate different functions and signaling pathways in response to drug-induced toxicity. Here, we mainly review and discuss our current molecular understanding of the mechanisms through which FOXM1 in cancer cells executes these new roles, and thereby induces therapy resistance and inhibits apoptosis in a variety of human cancers. We also discuss the opportunity and challenges for therapeutically targeting FOXM1 to induce apoptosis in drug-resistant cancers.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
